SCHEMBL6442015

SCHEMBL6442015

COC(=O)CSc1nc(N)nc(-c2ccccc2)c1C#N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.66
HPGD P15428 5/20 0.66
MAPT P10636 5/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
HSD17B10 Q99714 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
TSHR P16473 2/20 0.56
USP2 O75604 1/20 0.56
POLB P06746 1/20 0.56
ALOX15 P16050 1/20 0.56
ALOX12 P18054 1/20 0.56
RAB9A P51151 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
ADORA1 P30542 10/20 0.53
ADORA2A P29274 8/20 0.53
ADORA3 P0DMS8 1/20 0.53
KDM4E B2RXH2 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445310 0.86 HPGD (0.64) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL13913674 0.82 ALDH1A1 (0.82) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL6444715 0.80 ALDH1A1 (0.65) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL6442931 0.80 ADORA1 (0.57) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL4908319 0.78 MAPT (0.70) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL6446335 0.77 ADORA1 (0.60) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL6440883 0.77 ADORA1 (0.67) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL6440806 0.76 ADORA1 (0.58) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL6442594 0.76 ADORA1 (0.71) MAPTADORA1ADORA2AADORA3RXFP1
SCHEMBL6441334 0.76 ADORA1 (0.61) ALDH1A1HPGDMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885HPGD 915/4885MAPT 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.